Sacral Nerve stimulators are surgically implanted during sacral nerve stimulation (SNS). The sacral nerve stimulator functions as a bladder and intestinal pacemaker, just like a cardiac pacemaker. Urinary urgency, frequency, and urge incontinence are some of the symptoms of an overactive bladder that can be treated with sacral nerve stimulation (SNS). The market for sacral nerve stimulation will grow at a healthy CAGR of 14.07%, from its estimate value of $3.27 billion in 2021 to $10.70 billion by 2030.
Market Dynamics
Drivers Urinary incontinence in older women is influence by an aging population and cases of obesity, diabetes, hypertension, and smoking, which help to fuel the market’s expansion. Therefore, it is very likely that the demand for this market will rise with the increase in target patients in the upcoming years. In addition, over the forecast period, the market will be driven by the rising geriatric population worldwide, research expenditures, and technological advancements related to developing novel medical devices. Overactive bladder disorders, urge incontinence, urinary tract infections, and the rising number of patients with OAB and fecal incontinence are the main factors driving market expansion. Restraints Health risks associated with nerve stimulation and unfavorable government regulations limit the market’s growth. In addition, the high price tags attached to the treatments will restrain market expansion. The growth rate of sacral nerve stimulation will be further impact by concerns about contraindications and side effects of the device. Opportunity The market expansion is most likely to be successful in underserved areas with unmet medical needs and technological advancements to reduce associated infections. Lung cancer screening programs will have new commercial opportunities due to the aging population. According to a study publish in Therapeutic Advances in Urology, urinary tract infections (UTIs) were the most common infections seen in outpatient settings (2019). Elderly women were disproportionately affect by UTIs, with 205 (or 11% of the population under investigation) having UTIs. By stimulating demand for the therapy, these populations will probably accelerate the segment’s growth.Market Segmentation
Product Insights Due to the rising prevalence of OAB and fecal incontinence, it is anticipate that the external SNS sector will experience the fastest growth during the project period. It primarily regulates the bladder by electrically stimulating the sacral nerves with the aid of external devices. The implantable devices market will continue to expand significantly during the anticipate period due to rising rates of fecal incontinence, pelvic pain, and urinary incontinence. Application Insights Urinary and fecal incontinence is anticipate to be the fastest-growing and most considerable market segment over the anticipate time frame. The increase in patients suffering from UTIs, OABs, and anal sphincter injuries is directly related to the expansion of this market. Fecal impaction, obstetric trauma, voiding dysfunction, interstitial cystitis, and other conditions can also contribute to fecal incontinence. As a result, this market is being driven forward by the rising prevalence of fecal and urine incontinence. Regional Insights Due to rising treatment awareness, the prevalence of OAB and urge incontinence, and the presence of well-established healthcare facilities in the region, North America ruled the entire market and will continue to grow at a strong CAGR. Furthermore, the market in this region is anticipated to be driven by the rapid adoption of technically sophisticated medical products, such as implantable SNS devices. The development of the local market for sacral nerve stimulation is additionally being positively impacted by rising reimbursements for technological advancements in devices and therapeutic methods. North America drove the market and is projected to extend further at areas of strength for a because of expanding mindfulness about the treatment, pervasiveness of OAB and ask incontinence and presence of deep rooted medical care offices in the locale. Besides, fast reception of mechanically progressed clinical items, like implantable SNS gadgets, is additionally expected to drive the market around here. Furthermore, expanding repayments for advancements in gadgets and treatment methodology is decidedly influencing the development of the territorial sacral nerve excitement market. Asia Pacific is assessed to extend at the most elevated CAGR from 2018 to 2026 because of expanding number of patients experiencing waste incontinence and urinary incontinence. Also, different mindfulness programs by the NGOs will assist with supporting the item interest. Presence of an enormous number of key organizations in economies, like China and Japan, is likewise driving the market. Key players Nuvectra, Cogentix Medical, Teleflex, B. Braun Melsungen AG, Medline Industries, Inc., Medtronic PLC, Axonics Modulation Technologies, Inc., Fuji Systems Corporation, Cook Medical Group, Inc., Bard Medical, and Coloplast Ltd are a few of the major companies in the global Sacral nerve stimulation market. Recent Developments- The next-generation recharge-free device in the InterStim portfolio, InterStim X, was approved by the US Food and Drug Administration in 2022, according to a statement from Medtronic plc. Delivering sacral neuromodulation (SNM) therapy with the InterStim system is a cutting-edge therapeutic option and the most individualized system available.
- Axonics Modulation Technologies Inc. and Micro Systems Technologies (MST) formed a strategic partnership in March 2021 to produce an implantable sacral neuromodulation device that is not rechargeable.
